IPHA logo

Innate Pharma SA (IPHA) Company Overview

Profile

Full Name:

Innate Pharma S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

October 17, 2019

Indexes:

Not included

Website:

http://www.innate-pharma.com

Description:

Innate Pharma SA is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. They work on harnessing the body's immune system to fight tumors, aiming to improve patient outcomes through advanced therapies and collaborations in the field of oncology.

Key Details

Price

$2.14

Market Cap

$173.49 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$56.19 M(+7.46% YoY)

Annual EPS

-$0.10(+87.35% YoY)

PE Ratio

-

Annual ROE

-14.20%

Annual Debt To Equity

0.75

Beta

0.53

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 21, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 6, 25 HC Wainwright & Co.
Buy
Jan 17, 25 HC Wainwright & Co.
Buy
Dec 9, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Nov 12, 24 HC Wainwright & Co.
Buy
Sep 13, 24 HC Wainwright & Co.
Buy
Jun 12, 24 HC Wainwright & Co.
Buy
May 15, 24 HC Wainwright & Co.
Buy
Apr 11, 24 HC Wainwright & Co.
Buy
Mar 22, 24 HC Wainwright & Co.
Buy

Screeners with IPHA included

Growing Shares Outstanding
Best performing stocks last 3 months
Stocks above SMA 50
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
Stocks above SMA 200
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.14
IPHA price is $2.14

Price All-time High

$8.20
IPHA price is currently -73.86% below its historical high of $8.20

Price Analysts Target

-
IPHA price consensus analysts' forecast is unknown

Price Today Change

+1.57%
IPHA price is up +1.57% today

Price YTD Change

+16.47%
IPHA price is up +16.47% since January 1st

Price 3-Year Change

-29.73%
IPHA price is down -29.73% over the past 3 years

Market cap

Market Cap

$173.49 M
IPHA market capitalization is $173.49 million

Market Cap 3-Year Change

-28.64%
IPHA market capitalization is down -28.64% over the past 3 years

Market Cap All-time High

$646.81 M
IPHA market capitalization is currently -73.18% below its historical high of $646.81 million

Market Cap Sector Rank

54.19%
IPHA market capitalization is higher than 54.19% of companies in Healthcare sector

Technical

Beta

0.53
IPHA beta is 0.53

200-day SMA

$2.10
IPHA price is currently +2.06% above its 200-day simple moving average

14-day RSI

52.52
IPHA 14-day relative strength index is 52.52

30-day Relative Volume

0.12
IPHA 30-day relative volume is 0.12

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$56.19 M
IPHA annual revenue is $56.19 million

Annual Revenue Analysts Estimate

$54.96 M
IPHA annual revenue is currently +2.23% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+7.46%
IPHA annual revenue is up +7.46% year-on-year

Annual Revenue Sector Rank

48.99%
IPHA annual revenue is higher than 48.99% of companies in Healthcare sector

Profit

Annual Gross Profit

-
IPHA annual gross profit value is unknown

Annual Gross Margin

-
IPHA annual gross profit margin value is unknown

Annual Operating Profit

-$13.72 M
IPHA annual operating income is -$13.72 million

Annual Operating Margin

-24.41%
IPHA annual operating profit margin is -24.41%

Annual Net Income

-$8.20 M
IPHA annual net profit is -$8.20 million

Annual Net Margin

-14.59%
IPHA annual net profit margin is -14.59%

EPS

Annual EPS

-$0.10
IPHA annual earnings per share is -$0.10

Annual EPS Analysts Estimate

-
IPHA annual earnings per share consensus analysts' forecast is unknown

Annual EPS 1-Year Change

+87.35%
IPHA annual earnings per share is up +87.35% year-on-year

Annual EPS Sector Rank

80.62%
IPHA annual earnings per share is higher than 80.62% of companies in Healthcare sector

ROA & ROE

Annual ROA

-3.84%
IPHA annual return on assets is -3.84%

Annual ROE

-14.20%
IPHA annual return on equity is -14.20%

EBIT & EBITDA

Annual EBIT

-$7.50 M
IPHA annual earnings before interest & taxes is -$7.50 million

Annual EBITDA

-$1.99 M
IPHA annual EBITDA is -$1.99 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
IPHA price to earnings ratio value is unknown

PE Ratio Sector Rank

-
IPHA price to earnings ratio is unknown

PB Ratio

PB Ratio

5.62
IPHA price to book ratio is 5.62

PB Ratio Sector Rank

85.08%
IPHA price to book ratio is higher than 85.08% of companies in Healthcare sector

PS Ratio

PS Ratio

-
IPHA price to sales ratio value is unknown

PS Ratio Sector Rank

-
IPHA price to sales ratio is unknown

Enterprise value

Enterprise Value

$136.52 M
IPHA enterprise value is $136.52 million

Enterprise Value Sector Rank

52.04%
IPHA enterprise value is higher than 52.04% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
IPHA EV/EBITDA value is unknown

EV/EBITDA Sector Rank

-
IPHA EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

3.73
IPHA annual current ratio is 3.73

Annual Quick Ratio

-
IPHA annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.75
IPHA annual debt to equity ratio is 0.75

Annual Interest Coverage Ratio

-10.83
IPHA annual interest coverage ratio is -10.83

Risk & Stability

Piotroski F-Score

-
IPHA piotroski f-score value is unknown

Altman Z-Score

-0.99
IPHA altman z-score is -0.99

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$203.61 M
IPHA annual total assets is $203.61 million

Annual Non Current Assets

$39.99 M
IPHA annual long term assets is $39.99 million

Annual Current Assets

$163.61 M
IPHA annual total current assets is $163.61 million

Annual Cash & Cash Equivalents

$78.05 M
IPHA annual cash & cash equivalents is $78.05 million

Equity

Annual Book Value

$57.37 M
IPHA annual book value is $57.37 million

Annual Working Capital

$119.80 M
IPHA annual working capital is $119.80 million

Liabilities

Annual Total Liabilities

$146.24 M
IPHA annual total liabilities is $146.24 million

Annual Total Long Term Liabilities

$102.42 M
IPHA annual total long term liabilities is $102.42 million

Annual Current Liabilities

$43.81 M
IPHA annual total current liabilities is $43.81 million

Annual Accounts Payable

$9.46 M
IPHA annual accounts payable is $9.46 million

Debt

Annual Total Debt

$44.10 M
IPHA annual total debt is $44.10 million

Annual Total Debt 1-Year Change

-2.68%
IPHA annual total debt is down -2.68% year-on-year

Annual Long Term Debt

$34.22 M
IPHA annual long term debt is $34.22 million

Annual Short Term Debt

$9.88 M
IPHA annual short term debt is $9.88 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$69.90 M
IPHA annual total expenses is $69.90 million

Annual Operating Expenses

$69.90 M
IPHA annual total operating expenses is $69.90 million

Annual Cost Of Goods Sold

-
IPHA annual cost of goods sold value is unknown

Annual SGA

$12.72 M
IPHA annual SGA is $12.72 million

Annual D&A

$5.51 M
IPHA annual depreciation & amortization is $5.51 million

Annual Interest Expense

$692.90 K
IPHA annual interest expense is $692.90 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$35.25 M
IPHA annual cash flow from operations is -$35.25 million

Annual CFO 1-Year Change

-74.49%
IPHA annual cash flow from operations is down -74.49% year-on-year

Annual CFI

$22.34 M
IPHA annual cash flow from investing activities is $22.34 million

Annual CFI 1-Year Change

+1028.33%
IPHA annual cash flow from investing activities is up +1028.33% year-on-year

Annual CFF

-$2.13 M
IPHA annual cash flow from financing activities is -$2.13 million

Annual CFF 1-Year Change

-10.41%
IPHA annual cash flow from financing activities is down -10.41% year-on-year

Free CashFlow

Annual FCF

-$37.79 M
IPHA annual free cash flow is -$37.79 million

Annual FCF 1-Year Change

-76.73%
IPHA annual free cash flow is down -76.73% year-on-year

CAPEX

Annual CAPEX

$2.55 M
IPHA annual capital expenditures is $2.55 million

Annual CAPEX 1-Year Change

+115.09%
IPHA annual capital expenditures is up +115.09% year-on-year

Institutional Ownership

Similar stocks

CYBN logo
Cybin (CYBN)
MOLN logo
Molecular Partners AG (MOLN)
ADCT logo
ADC Therapeutics SA (ADCT)
JYNT logo
Joint (JYNT)
PLX logo
Protalix BioTherapeutics (PLX)
PBYI logo
Puma Biotechnology (PBYI)
INFU logo
InfuSystem Holdings (INFU)
CARGO Therapeutics (CRGX)
STXS logo
Stereotaxis (STXS)

FAQ

  • What is the ticker symbol for Innate Pharma SA?
  • Does Innate Pharma SA pay dividends?
  • What sector is Innate Pharma SA in?
  • What industry is Innate Pharma SA in?
  • What country is Innate Pharma SA based in?
  • When did Innate Pharma SA go public?
  • Is Innate Pharma SA in the S&P 500?
  • Is Innate Pharma SA in the NASDAQ 100?
  • Is Innate Pharma SA in the Dow Jones?
  • When was Innate Pharma SA's last earnings report?
  • When does Innate Pharma SA report earnings?

What is the ticker symbol for Innate Pharma SA?

The ticker symbol for Innate Pharma SA is NASDAQ:IPHA

Does Innate Pharma SA pay dividends?

No, Innate Pharma SA does not pay dividends

What sector is Innate Pharma SA in?

Innate Pharma SA is in the Healthcare sector

What industry is Innate Pharma SA in?

Innate Pharma SA is in the Biotechnology industry

What country is Innate Pharma SA based in?

Innate Pharma SA is headquartered in France

When did Innate Pharma SA go public?

Innate Pharma SA's initial public offering (IPO) was on October 17, 2019

Is Innate Pharma SA in the S&P 500?

No, Innate Pharma SA is not included in the S&P 500 index

Is Innate Pharma SA in the NASDAQ 100?

No, Innate Pharma SA is not included in the NASDAQ 100 index

Is Innate Pharma SA in the Dow Jones?

No, Innate Pharma SA is not included in the Dow Jones index

When was Innate Pharma SA's last earnings report?

Innate Pharma SA's most recent earnings report was on Nov 13, 2024

When does Innate Pharma SA report earnings?

The next expected earnings date for Innate Pharma SA is Mar 27, 2025